Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• The patient who have signed the informed consent;

• Histologically confirmed with NSCLC at stage III-IV

• Expected survival time is more than 2 month;

• Eastern Cooperative Oncology Group(ECOG) performance status was 0-2

Exclusion Criteria:

• Hemoglobin <8.0 g/dL, White blood cell <3 x 10^9/L; Platelet count <75 x 10^9/L; alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea nitrogen(BUN) and Creatinine(CR) more than normal limits on 3.0 times;

• Known or suspected allergy to the investigational agent or any agent given in association with this trial;

• Pregnant or lactating patients;

• Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;

• Patients who are suffering from serious autoimmune disease;

• Patients who had used long time or are using immunosuppressant;

• Patients who had active infection;

• Patients who are suffering from serious organ dysfunction;

• Patients who are suffering from other cancer;

• Other situations that the researchers considered unsuitable for this study.